The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24-2.85; P = 0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16-2.64; P = 0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00-2.07; P = 0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08-2.88; P = 0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).
INTRODUCTION
There is a general consensus that patients with AML who fail to achieve a complete hematologic response (CR) after one or two chemotherapy cycles can be defined as primary refractory (PRF). 1, 2 The outcome of these patients is usually very poor with only a small proportion rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of some pre-HSCT variables may help to identify PRF AML patients who can most likely benefit from transplantation. 3 In a recent retrospective analysis, the Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare (GITMO) reported the clinical outcome of 523 AML patients allotransplanted with an active disease after a myeloablative (MAC) or reduced-intensity (RIC) conditioning regimen over a 10-year (from 1999 to 2009) interval time. In line with the Center for International Blood and Marrow Transplant Research study, our analysis included not only PRF AML but also patients with a refractory relapse, untreated first relapse and untreated myelodysplastic syndrome (MDS)-related AML. The OS of these cohorts was analyzed according to the risk categories defined by the Center for International Blood and Marrow Transplant Research score, based on five pre-HSCT variables predictive of outcome (duration of initial response, presence or absence of circulating blasts, performance status, bone marrow karyotype and donor type). As in the original Center for International Blood and Marrow Transplant Research study, the OS at 3 years was 40% in the more favorable prognostic group of patients (score 0), 26% in the intermediate I risk group (score 1), whereas in the intermediate II risk group (score 2) and in the poor risk group (score 3), the OS was 18% (HR: 1.58, P = 0.040) and 5% (HR: 2.83, P o0.0001), respectively. 4 However, in both studies there was a substantial heterogeneity of the patients involved since the true PRF AML was only one-third of the whole analyzed cohort. By contrast, the European Bone Marrow Transplantation group reported factors predicting the outcome of 168 patients only with PRF AML, receiving unrelated donor stem cell transplantation. In this study, the 5-year OS was 22% and relevant factors associated with improved survival were the number of induction chemotherapy cycles (less than three), the degree of bone marrow blast infiltration (below 38%) and recipient CMV seropositivity. These relatively simple clinical findings allowed us to define four prognostic groups with survival rates ranging between 44 and 0%. 5 In this study, we planned to analyze not only transplants performed using un unrelated donor but also to extend the investigation to patients receiving a graft from a sibling or even a cord blood (CB) unit. The study reported here refers to patients with real PRF AML transplanted in Italy between 1999 and 2012.
PATIENTS AND METHODS

Data sources
Twenty-six Italian centers performing HSCT in adult patients and belonging to the national bone marrow transplantation network (GITMO) participated in this retrospective, multicenter observational study (see details in Supplementary Appendix 1). Permission to perform this study was obtained from the GITMO Clinical Studies Board. The procedures followed were in accordance with the ethical standards of GITMO Clinical Studies Board as well as with the Declaration of Helsinki. Data were retrieved from the GITMO database and missing data or specific queries were requested from each center.
Patients, transplant procedures and definitions
We analyzed the clinical outcome of 227 patients diagnosed between 1999 and 2012 with a de novo AML or secondary AML to a previous MDS, chronic myelomonocytic leukemia, Ph negative chronic myeloproliferative neoplasm or chemotherapy treatment. Patients' disease status at transplantation included PRF AML defined as failure to achieve a complete Abbreviations; BM = bone marrow; CMML = chronic myelomonocytic leukemia; CMV = cytomegalovirus; HSCT = hematopoietic stem cells transplant; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasms; PB = peripheral blood; PS = performance status; RIC = reduced-intensity conditioning.
a Log-rank test. b HR, hazard ratio estimated by a Cox proportional hazard univariate model.
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response after two cycles with standard dose chemotherapy or one cycle based on high-dose cytarabine in combination with an anthracycline. The stem cell source was represented by BM, peripheral blood (PB) or CB. The cytogenetic and molecular risk definition of patients was performed according to the European LeukemiaNet recommendations. 6 The PS was calculated according to the Karnofsky scale. Ex vivo or in vivo T-cell depletion was performed by positive selection of CD34+ cells or by anti-thymocyte globulin infusion given as a part of conditioning regimen, respectively. Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were diagnosed and graded according to standard criteria. 7, 8 Neutrophil and platelet engraftment were defined as the first of three consecutive days with an absolute neutrophil count 40.5 × 10 9 /L and an untransfused platelet count 420 × 10 9 /L.
Statistical analysis
The main end points of the study were OS defined as time from transplant to death from any cause and leukemia-free survival (LFS) as defined by European Bone Marrow Transplantation, as the time from response after transplant to death for any cause or relapse. 9 Observations were censored from the date the patient was last known to be alive without any evidence of relapse. OS and LFS were assessed using the Kaplan-Meier method and compared between risk groups using the log-rank test. Responding patients were considered those who had obtained, after HSCT at least a iCR (defined as bone marrow blasts o5%, absolute neutrophil counts 41 × 10 9 /L and platelet count 420 × 10 9 /L. 1 Multivariate analyses were performed using the Cox proportional hazard model, including those variables considered in univariate analysis, related to patient or disease characteristics. Proportional hazard assumption was tested for all estimated models. The score system was built according to multivariate analysis results; a rate of one was assigned to each risk factor identified. For each patient, final score was calculated as the sum of risk factors. Relapse incidence (RI) and non-relapse mortality (NRM) as well as probabilities of acute and cGvHD were calculated using a competing risk model. NRM e RI were assessed on all patients; early deaths and deaths occurring in CR without previous relapse were defined as non-relapse deaths, whereas relapsed patients and non-responders were considered competing events. Patients alive in CR were censored at date of last contact. Acute and chronic GvHD effect on survival was assessed independently with a Cox proportional hazard model as time-dependent variables. 9 The type I error rate was fixed at 0.05 for determination of factors associated with time-to-event outcomes. Statistical analysis was performed using R (version 3.1.2) software package (R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).
RESULTS
Patient and transplant characteristics
Overall, 227 patients from 26 GITMO centers were included in the final analysis. Patient characteristics are listed in Table 1 . The median age at HSCT was 49 years (18-72) and 57% of patients were male. At diagnosis, 64% had a de novo AML, 36% had a secondary AML (chemotherapy-related) or MDS or chronic myeloproliferative neoplasm. The number of chemotherapy cycles received before transplant was more than 2 in 98 patients (45%), whereas 97 patients (44%) received 2 chemotherapy cycles. In addition, 25 patients (11%) were considered PRF after only one cycle of chemotherapy containing high-dose cytarabine (HD-ARA-C). Median time from diagnosis to transplant was 6 months (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and in 88% was ⩾ 3 months. An intermediate II or adverse karyotype was detected in 58% of patients, a greater or equal than 25% BM infiltration or any level of PB blasts was found in 60% and a pre-HSCT Karnofsky score less than 90 was present in 45%. The stem cell source was the PB in 63%, the BM in 26% and the CB in 11%. Donors were HLA identical sibling in 48%, related mismatched (including haploidentical transplant) in 20%, CB in 11% and unrelated in 19%. A female donor for a male patient was used in 24% of transplants. Anti-CMV antibodies were present in 65% of the donors and in 87% of the recipients. Sixty-nine percent of patients received a MAC and 31% a RIC program. Fifty percent of patients received a T-cell depletion, 92% in vivo and 8% ex vivo.
Outcome and GvHD After transplantation, 124 patients (54%) achieved CR after a median time of 34 days (13-134), 71 patients did not (31%) and 32 (14%) died early (within 40 days from HSCT). Sixty-nine non-responder patients died, whereas two patients were still alive at last contact. Among remitters, 28 died in remission and 30 survived; 66 relapsed after a median time of 3 months (1-31). Of the latter, 61 died of disease and 5 survived. Overall, 37 patients remained alive, 33 in CR and 4 with active disease (Figure 1 ). Engraftment data were available for 191 patients; neutrophil and platelets engraftments were observed after a median of 17 (9-52) and 17 (3-150) days, respectively.
The median OS of the whole patient cohort was 5.3 months (IQR 4.5-6.7), whereas median follow-up of survivor was 30 months (1.8-148). The OS of the whole patient population is 14% (Figure 2 Allogeneic transplant in refractory AML E Todisco et al panel a), whereas the LFS of responder patients is 23% at 3 years ( Figure 2, panel b) . At 100 days from transplant, cumulative incidence of aGvHD was 35% (26% grade I-II and 9% grade III-IV). Overall, no statistically significant effect of aGvHD on OS was observed (P = 0.906) (data not shown). However, patients with grade I-II aGvHD had a better OS than patients without aGvHD, (HR: 0.87, 95% CI: 0.62-1.24), although this result did not reached statistically significance. Cumulative incidence of cGvHD at 1 year after transplant was 24% (14% limited and 10% extended). No significant effect of cGvHD on OS was observed (HR: 0.72, P = 0.1488) (data not shown). The 3 year cumulative incidence of NRM and RI was 27% and 61%, respectively (Figure 3 ).
Prognostic factors and definition of a new prognostic score By univariate analysis, the median time from diagnosis to HSCT less than 3 months, the favorable/intermediate I cytogenetic risk, the number of BM blasts less than 25% or the absence of blasts in the PB and the Karnofsky PS equal or greater than 90 were factors associated with a significantly better survival (Table 1) . Furthermore, the OS according to the number of chemotherapy cycles received before HSCT showed a significant difference between the 25 patients that received a single chemotherapy cycle including HD-ARA-C as compared to the 195 patients who received ⩾ 2 cycles (Figure 4) . By multivariate analysis, risk factors significantly associated with a worst survival were: more than 2 chemotherapy cycles before transplant, (HR: 1.87; 95% CI: 1.24-2.81; P = 0.0028), a number of BM blasts greater or equal than 25% or any level of blasts in PB (HR: 1.75; 95% CI: 1.16-2.64; P = 0.0078), being more than 60 years old at transplant (HR: 1.77; 95% CI: 1.08-2.88; P = 0.0223) and adverse cytogenetics (HR: 1.44; 95% CI: 1.00-2.07; P = 0.0508) ( Table 2 ). On the basis of these factors, we set up a new scoring system that stratified the population in three groups: the most favorable prognostic group with score 0 (no adverse prognostic factor or 1 prognostic factor) shows a 46% (CI 95%: 35-61%) survival at 1 year and a 32% (CI 95%: 21-49%) survival at 3 years. For patients with score 1 (2 adverse prognostic factors), we estimated a 24% (CI 95%: 16-38%) survival at 1 year and a 10% (CI 95%: 5-23%) survival at 3 years. Patients with score 2 (3 or 4 adverse prognostic factors) shows a 15% (CI 95%: 8-30%) survival at 1 year ( Figure 5 ). Finally, we analyzed whether the proposed prognostic score could work properly for the different types of donors. Interestingly, the score defines significantly different outcomes for patients transplanted using family or alternative donors ( Figure 6, panel a and b) . 
DISCUSSION
In this paper, we report the clinical outcome of patients with PRF AML who received an allogenic transplant in Italy between 1999 and 2012. By multivariate analysis, the factors associated with a worst survival rate were the number of chemotherapy cycles (more than two) before the conditioning regimen for transplantation, the leukemia burden at conditioning (a BM blast infiltration greater than 25% or the presence of blasts in the PB), a poor molecular/cytogenetic profile and age at the time of transplant more than 60. To note, the T-cell depletion had no impact on survival. On the basis of these variables, we set up a new prognostic score, specific for PRF AML, that is able to identify patients with an acceptable expected survival (32% at 3 years for patients with score 0) as compared with those with a very dismal prognosis (3% alive at 2 years for patients with score 2). To our knowledge, this paper reports the largest cohort of PRF AML receiving an allogenic transplant from either sibling or unrelated donors and from any stem cell source (including CB). In addition, the prognostic score we are proposing is based on a few clinical findings, easily applicable to all patients who may be considered for such a salvage transplant procedure. Interestingly, the failure to achieve a CR after more than two chemotherapy cycles and the extent of BM blast infiltration were recognized as negative prognostic factors also in the European Bone Marrow Transplantation analysis. 5 This observation suggests that when a chemotherapy resistant AML is present, we should avoid exposing patients to repeated useless chemotherapy cycles and at least for fit patients younger than 60 years, an urgent, alternative strategy based on allogeneic transplant should be rapidly pursued including the choice of a family mismatched haplo donor. [10] [11] [12] To overcome the problem of performing an allogenic transplant despite a significant leukemic burden present at time of conditioning, different strategies have been proposed. Among them it is worth mentioning the sequential FLAMSA chemotherapy followed by busulfan-based reduced conditioning, which can obtain a satisfactory LFS even in patients with active disease. 13 Alternative approaches such as, the use of iodine-131 (131I), anti-CD45 antibody combined with fludarabine and 2 Gy TBI 14 or a total marrow irradiation (TMI) dose escalation up to 15 Gy combined with CY/VP16 15 have also been proposed with acceptable toxicities and encouraging outcomes to create an improved HSCT strategy for advanced AML. Finally, post-transplant treatments Abbreviations: BM = bone marrow; CI = confidence interval; CMML = chronic myelomonocytic leukemia; CMV = cytomegalovirus; HSCT = hematopoietic stem cells transplant; HR = hazard ratio estimated by a Cox proportional hazard univariate model; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasms; PB = peripheral blood; PS = performance status.
with new drugs such as 5-Azacitidine, 16, 17 sorafenib, 18 midostaurin 19 or cells 13, 20 can be considered to reduce the risk of leukemia relapse. When compared with what is reported by Craddock on the European Bone Marrow Transplantation registry data, in the GITMO data set we found that age and cytogenetics are of paramount importance and always more relevant than any other biologic or genetic variable. Data on the impact of recipient age on the outcome after allogeneic transplantation are conflicting. Introduction of RIC regimens has made allotransplant procedure more feasible in elderly AML patients with significant reduction of NRM and an improved outcome. However, specific data addressing the impact of age on the post-HSCT outcome of elderly PRF AML patients is not available. In addition, we could not confirm the prognostic impact of the positive CMV serology, 5 which remains an important speculative issue when considering the immune modulation played by CMV on donor T cells. 21 Although a reduced risk of early relapse has been reported in AML patients with CMV reactivation after transplantation, 22 other studies have underlined a detrimental effect of CMV seropositivity on non-relapse mortality as well as LFS and OS. 23 To set up a clinically meaningful risk score, the variables included in the multivariate analysis were not only those which proved significant 122 (55) 119 (60) 78 (40) 40 (18) 81 (42) 110 (58) 187 ( 24 derived from a wide application of genome next-generation sequencing approaches, could further delay the transplant procedure in chemo refractory patients although the benefit of such innovative drugs used as a bridge may prove quite effective. Beyond the retrospective nature of this study, the relatively low proportion of family mismatched transplants performed during the study period represents an additional possible limit to of this analysis. Since this modality of transplant has remarkably increased over the last 3 years, an additional separate analysis to evaluate the clinical impact of these transplants is justified.
In conclusion, chemo resistant disease remains a dramatic condition for any AML patient even when an allogeneic transplant option is offered. A few simple clinical factors can be used to create a risk score that helps to identify patients who most likely benefit from such a salvage procedure. Therefore, if a family or unrelated donor is not immediately available either a CB unit or a haploidentical transplant should be offered promptly. To validate the benefit of such a prompt treatment algorithm in PRF AML patients, in a prospective setting, a clinical trial has now been launched by GITMO (the Gandalf-1 study ClinicalTrial.gov NCT01814488)
